Showing 1041-1050 of 6040 results for "".
Long-Term Effects of Neuromodulators on Aging
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/long-term-effects-of-neuromodulators-on-aging/18810/Shannon Humphrey, MD discusses the cumulative anti-aging benefits of long-term treatments with botulinum toxin type A. She shares her observations from the bench and offers a review of what the literature shows to support her recommendation for regular conservative neuromodulator treatments to improAdvances in Reconstructive Surgery
https://practicaldermatology.com/topics/skin-cancer-photoprotection/advances-in-reconstructive-surgery/18675/Murad Alam, MD, talks to DermTube Journal Club Host Joshua Zeichner, MD about what's new in reconstructive surgery. Dr. Alam discusses advances in fastening and adhesives to minimize scars, as well as the benefits of lasers, energy-based devices, and ultrasound to smooth scars, further minimizing thValeant Business Update; Melanoma Drugs Approved
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-valeant-business-update-melanoma-drugs-approved/18679/In this edition of DermWireTV from the editors of Practical Dermatology® magazine and DermWire.com, we take a look at Valeant's warning of disruption of dermatology business following its break from specialty pharmacy Philidor. Plus, an update on Melanoma Therapeutics, including approvals of ImlygicTopical Treatment Considerations for Psoriasis
https://practicaldermatology.com/topics/psoriasis/topical-treatment-considerations-for-psoriasis/18845/Jerry Bagel, MD and Neil J. Korman, MD discuss topical treatment options for treating patients with mild psoriasis. They share insights about the effect of vehicles on compliance, particularly when treating patients with scalp psoriasis.Epiduo Forte Approved; Facial Aesthetics By Age
https://practicaldermatology.com/topics/practice-management/dermwiretv-epiduo-forte-approved-facial-aesthetics-by-age/18870/Galderma's non-antibiotic Epiduo Forte (Adapalene 0.3% and benzoyl peroxide 2.5%) approved for topical management of acne vulgaris. Trends reveal differences in women's facial cosmetic surgery by age. AMA and CMS offer ICD-10 help. Plus: An Update on NewDerm LIVE.Cosentyx Approved, Silver is Bad for Burns
https://practicaldermatology.com/topics/psoriasis/dermwiretv-cosentyx-approved-silver-is-bad-for-burns/18971/FDA approves the first IL-17 inhibitor for psoriasis—Cosentyx from Noavartis, and new research explains why silver sulfadiazine is bad for burn wounds. Plus, we get an update on the Dermatology Summit and the state of innovation in dermatology, and learn about Phase III trials for Dermira's Cimzia.DermInsider: Coming to DermTube.com
https://practicaldermatology.com/topics/practice-management/derminsider-coming-to-dermtube-com/19077/DermInsider: A Video Discussion Series Hosted by Neal Bhatia, MD. Expert Panelists. Unfiltered. New episodes coming to DermTube.com.Incorporating Skincare into Practice
https://practicaldermatology.com/topics/practice-management/incorporating-skincare-into-practice--ipisenol/19090/What's the best way to incorporate sunscreen, moisturizers, cleansers, and anti-aging topicals into your practice? Jennifer Linder, MD, FAAD offers tips for patient education and product selection.Dr. Joel Schlessinger discusses the importance of clinical research in your practice
https://practicaldermatology.com/topics/practice-management/dr-joel-schlessinger-discusses-the-importance-of-clinical-research-in-your-practice/19135/With hundreds of new products, procedures and technologies becoming available every day, it is important to keep up with the changing medical world. One way to do this is through clinical research at your practice. In this video, Dr. Joel Schlessinger discusses how he began his clinical research stuDermwireTV — Revance’s Neurotoxin Promising, Celebs Fight Melanoma with L’Oreal
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-mdash-revance-rsquo-s-neurotoxin-promising-celebs-fight-melanoma-with-l-rsquo-oreal/19138/In this weeks DermwireTV, patient safety is explored, L'Oreal supports melanoma research and Revance reports positive data for novel neurotoxin.